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The goal here is to describe our current understanding of heme metabolism and the
deleterious effects of “free” heme on immunological processes, endothelial function,
systemic inflammation, and various end-organ tissues (e.g., kidney, lung, liver, etc.),
with particular attention paid to the role of hemopexin (HPX). Because heme toxicity
is the impetus for much of the pathology in sepsis, sickle cell disease (SCD), and
other hemolytic conditions, the biological importance and clinical relevance of HPX,
the predominant heme binding protein, is reinforced. A perspective on the function
of HPX and haptoglobin (Hp) is presented, updating how these two proteins and
their respective receptors act simultaneously to protect the body in clinical conditions
that entail hemolysis and/or systemic intravascular (IVH) inflammation. Evidence from
longitudinal studies in patients supports that HPX plays a Hp-independent role in genetic
and non-genetic hemolytic diseases without the need for global Hp depletion. Evidence
also supports that HPX has an important role in the prognosis of complex illnesses
characterized predominantly by the presence of hemolysis, such as SCD, sepsis,
hemolytic-uremic syndrome, and conditions involving IVH and extravascular hemolysis
(EVH), such as that generated by extracorporeal circulation during cardiopulmonary
bypass (CPB) and from blood transfusions. We propose that quantitating the amounts
of plasma heme, HPX, Hb-Hp, heme-HPX, and heme-albumin levels in various disease
states may aid in the diagnosis and treatment of the above-mentioned conditions, which
is crucial to developing targeted plasma protein supplementation (i.e., “replenishment”)
therapies for patients with heme toxicity due to HPX depletion.
Keywords: hemopexin, heme, haptoglobin, iron, plasma protein therapeutics, hemolytic index, hemolysis,
erythrophagocytosis
Abbreviations: Mr, Apparent Molecular weight; CPB, Cardiopulmonary bypass; CD91/LRP1, CD163, Cluster of
differentiation; DF, Dengue fever; DHF, Dengue hemorrhagic fever; EVH, Extravascular hemolysis; FLVCR, Feline leukemia
virus Sub group C receptor; FPN, Ferroportin; Hp, Haptoglobin; HO, Heme oxygenase; HPX, Hemopexin; HIV, Human
immunodeficiency virus; IVH, Intravascular hemolysis; IL-6, interleukin-6; MetHb, Methemoglobin; Mb, Myoglobin; NQO1,
NADP(H):quinone oxido-reductase 1; NET, Neutrophil extracellular trap; NO, Nitric oxide; NOS, Nitric oxide synthase;
PMVEC, Pulmonary artery endothelial cell; PMVEC, Pulmonary microvasculature endothelial cell; PHP, pyridoxalated Hb
polyoxethylene conjugate; ROS, Reactive oxygen species; RBC, red blood cell; SCD, Sickle cell disease; TNF, tumor necrosis
factor; VWF, Von Willibrand Factor.
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Introduction
The low, essentially constant leakage of hemoglobin (Hb) from
red blood cells (RBCs), termed trivial hemolysis, is well-tolerated;
however, both intravascular (IVH) and extravascular (EVH)
hemolysis induce severe inflammation and potential tissue
dysfunction. This pathology is due to heme (iron-protoporphyrin
IX) released from methemoglobin (metHb, Bunn and Jandl,
1968). Unless bound to proteins, the redox-active heme-iron
participates in oxygen radical reactions that covalently modify
protein, lipid, carbohydrate and/or nucleotides, which then lead
to tissue damage. Cellular heme toxicity, first described in 1991
(Balla et al., 1991b), derives partly from heme alone and also
through heme-mediated sensitization of cells to subsequent
stimuli including reactive oxygen species from activated human
neutrophils, inflammatory cytokines, and NO. Cells rely on
“extracellular antioxidants,” i.e., the proteins in biological fluids
to prevent such radical chemistry by sequestering the heme and
its iron (Halliwell and Gutteridge, 1990). Thus, haptoglobin (Hp)
binds Hb, the source of heme that is bound by hemopexin
(HPX), and transferrin binds iron. In plasma, HPX targets
heme to the liver parenchymal cells for heme catabolism, iron
storage, and re-distribution. In barrier tissues, HPX targets heme
to brain neurons (Hahl et al., 2013). Normally, HPX recycles
after heme delivery whereas the Hp-Hb complex is degraded in
macrophages. Documented changes in plasma Hp and free Hb
levels provide clues as to the extent of hemolysis; but only HPX
and heme levels demonstrate problems with heme clearance.
Our purpose is to provide a new perspective on the roles of the
HPX and Hp systems in human diseases in which they protect
against Hb-derived heme toxicity and body iron loss. HPX is
not an acute phase protein in humans, as is Hp, and because of
additional differences between these systems in humans and in
mice, we focus on reviewing in vivo data from human subjects
and rhesus monkey research, and in vitro data from cultured
human cells. Throughout this review, we have used italic font to
emphasize key points and conclusions.
Our goal is to describe current understanding of heme
metabolism and the deleterious effects of “free” heme on
immunological processes, endothelial function, systemic
inflammation, and various end-organ tissues (e.g., kidney,
lung, liver, etc.), with particular attention paid to the protective
role of HPX. We propose that the model of a linear pathway
for the development of heme toxicity with HPX as a backup
system for Hp, i.e., acting only when Hp becomes depleted,
does not represent many situations in vivo. Examples from
patients and experimental animals provide evidence that HPX
and Hp act simultaneously in various niches of the body when
hemolysis occurs, both in the presence or absence of infection
and inflammation. HPX protects human endothelial (Balla
et al., 1993) and hepatic parenchymal (Larsen et al., 2010) cells
from direct heme toxicity and heme-sensitization (Balla et al.,
1991b). HPX protects human macrophages by limiting the
heme-mediated oxidation of lipoproteins (Camejo et al., 1998;
Smith, 2013) generating lipid peroxide- and iron loaded-LDL
(Balla et al., 1991a). Heme-mediated LDL oxidation contributes
to the pathogenesis of atherosclerosis (Camejo et al., 1998; Jeney
et al., 2002), heme being derived from ruptured plaques (Nagy
et al., 2010) and LDL from the extracellular intima.
Interest in the protective role of HPX has rapidly increased
during the past 5 years because the causative role of heme
in the pathophysiology of sepsis, sickle cell disease (SCD),
other hemolytic conditions and also in atherosclerosis (Balla
et al., 1991a; Nagy et al., 2010) has become accepted (Larsen
et al., 2010; Smith, 2011a,b; Ghosh et al., 2013; Schaer et al.,
2013; Smith, 2013; Belcher et al., 2014; Schaer et al., 2014;
Jung et al., 2015). Insights into how HPX acts in clinical
IVH and EVH have been obtained primarily through primate-
, rat-, mouse-, and human-based studies. While HPX’s role in
protection against heme-mediated inflammation and oxidative
damage is established, further studies are needed to confirm the
Hp-independent activity of HPX in hemolysis in various clinical
disease states in humans. We have therefore summarized and
reviewed both historical and recent observations on the HPX and
Hp systems in relevant human conditions and diseases. Finally,
we propose future research avenues related to heme metabolism
in human health and disease. These include quantitating the
amounts of plasma heme, HPX, Hb-Hp, heme-HPX, and
heme-albumin levels in various disease states to aid in the
diagnosis and treatment of diseases prominently characterized
by hemolysis and investigating the use of targeted plasma
protein supplementation (i.e., “replenishment”) therapies for
patients with heme toxicity due to HPX depletion. Although not
addressed here, α-1 microglobulin binds heme and free radicals
protecting particularly EVH sites (Akerstrom and Gram, 2014),
and when infused minimized pre-eclampsia-like symptoms from
Hb in perfused human placenta (May et al., 2011); and treated
pre-eclampsia in sheep (Wester-Rosenlof et al., 2014).
Structure and Function of Hemopexin and
Haptoglobin and their Role in Heme and
Hemoglobin Clearance in Intravascular
Hemolysis
The lysis of 1ml of blood containing 5 billion RBCs each with
∼289 million Hb molecules (Sears, 1999) could release∼ 1.45×
1018 Hbmolecules, which is 1000-fold higher than 20µMplasma
Hp molecules (6.82 × 1015) in the immediate plasma (550µl).
Given that total body plasma Hp would be∼2.8×1019 molecules
(and HPX on average an additional 1.8 × 1019 molecules if at
12.4µM (Drabkin, 1971), it is clear that Hb and heme loads
can be massive. Endothelial cells lack HPX receptors (Smith
and Morgan, 1979) and unregulated heme diffusion into and
metabolism by these cells, estimated to be ∼60 trillion cells in
the human body (Aird, 2005), represents a formidable asset and
heme “sink” but also a major target for heme toxicity.
The crystal structure of the equimolar heme-HPX complex
(Paoli et al., 1999) reveals the unique coordination of heme
that contributes to one of the highest affinities known, Kd less
than pM (Hrkal et al., 1974). Thus, HPX is the key defense
against the deleterious effects of heme on cells, particularly
hepatic, immune system and endothelial cells. Heme rapidly
dissociates from metHb that is quickly generated from HbO2A,
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even faster from sickle Hb (HbS; Hebbel et al., 1988) and also
from Hp-bound Hb; particularly in the presence of NO and ROS
including hypochlorous acid (Jeney et al., 2002), generated by
the respiratory burst of neutrophils and macrophages at sites
of inflammation. Ferro-Hb was relatively innocuous to porcine
endothelial cells in serum-free medium, whereas ferri-heme,
which readily released from globin to which it is bound less
tightly was toxic (Balla et al., 1993). The heme globin interaction
is stronger in cyano-Hb and in Hp-Hb preventing heme
uptake. HPX prevented the metHb toxicity (Balla et al., 1993).
Heme sensitizes cells to inflammatory cytokines, e.g., tumor
necrosis factor-α (TNF), which is toxic to human hepatocytes
(Larsen et al., 2010), and murine peritoneal macrophages
(Fortes et al., 2012); as well as to ROS including H2O2, which
predisposes porcine (Balla et al., 1991b) and human umbilical
(Jeney et al., 2002) endothelial cells to die. Two synergistic
mechanism by which heme causes necrosis of murine peritoneal
macrophages are: TNF expression from TLR4/Myd88 pathway
activation and TLR4-independent generation of ROS (Fortes
et al., 2012). Micromolar heme activates human neutrophils
triggering the oxidative burst and release of the chemokine
interleukin 8 (Graca-Souza et al., 2002), resulting in leukocyte
migration into tissues. In mice models of SCD, unless HPX
is present or replenished, heme causes endothelial cells to
present surface adhesion molecules leading to stasis and vaso-
occlusion in part via toll-like receptor-4 (TLR4) activation
(Belcher et al., 2014) and pulmonary endothelia to produce
neutrophil extracellular traps (Chen et al., 2014). Also, HPX
down-regulates lipopolysaccharide (LPS)-induced production of
TNF and IL-6 inflammatory cytokines in mouse bone marrow-
derived macrophages (Liang et al., 2009).
Within RBCs, heme in Hb is maintained in the reduced
state needed for oxygen binding. After lysis, this ferro-O2 Hb
is bound by Hp, then ferro-Hb-Hp and, finally, ferric-Hb-Hp
complexes are generated. For Hb transport, each Hp molecule
binds the equivalent of one tetramer of Hb [(αβ)4], as two
αβ globin dimers each monomer with its own heme bound
(Andersen et al., 2012). Hp sequesters Hb [Kd 10−15M (Lim
et al., 2001)] limiting Hb oxidation with heme release unless ROS
are present In humans, Hp-Hb complexes are endocytosed by the
cluster of differentiation receptor 163 (CD163) in mature tissue
macrophages present in the spleen, liver, lymph nodes, bone
marrow, lung, placenta, peritoneum, thymus, and the Kupffer
cells of the liver.
Differences between the affinity of human and mouse CD163
for their respective Hb-Hp complexes and for Hb itself indicate
that CD163 endocytosis of Hp-Hb (Kd 19 nM) rather than of
Hb is preferred in humans in contrast to mice (Etzerodt et al.,
2013). Nevertheless, the affinity of human CD163 for Hb (Kd
195 nM) is sufficiently high that the micromolar levels of Hb
documented in hemolytic conditions would result in CD163-
Hb binding (Receptor occupancy under equilibrium conditions
would be expected to be 50% with a ligand concentration at
the Kd value, and more than 90% occupancy at 100 × Kd
value). Furthermore, mice do not always make good models
of certain human inflammatory conditions that accompany
hemolysis including trauma, burns, and endotoxemia that have
some degree of hemolysis (Seok et al., 2013).
In IVH, the safe clearance of heme and Hb from the plasma
by receptor-mediated endocytosis is rapid: within 2–5min for
heme-HPX principally by liver parenchymal cells (Smith and
Morgan, 1981) in part via CD91/LRP1 (Hvidberg et al., 2005);
and within 10min for Hb-Hp complexes by macrophage CD163
(Delanghe and Langlois, 2001). Clearance will be impaired when
these two scavenger receptors are saturated with any of their
many known ligands; and also when Hp and HPX are depleted.
Heme is then reserved on human serum albumin (HSA) from
which it continuously dissociates. Non-protein bound heme
travels at uncontrolled rates across the plasma membrane of cells
via diffusion or possibly via channels or interacts with LDL.
The extracellular anti-oxidant protection of cells by HPX and
Hp against heme toxicity from Hb, along with their transport
function, are only part of the protective responses against heme
toxicity for the body. As first shown in 1992 (Balla et al., 1992),
the high activities of two intracellular enzymatic systems are key
to cell survival from heme toxicity by maintaining safe levels
of redox-active heme and iron. Heme oxygenases (HOs) break
down heme but in so doing release its iron as the tetrapyrrole
ring opens. This chemically reactive iron is rapidly stored within
the ferritin molecule via the ferroxidase activity of the H-
subunit. Heme and its iron can both be used for biochemical
and regulatory purposes or exported. It is now known that heme
and iron export systems (FLVCR and FPN1, respectively) and
the acceptor proteins, HPX and transferrin, respectively, are
also important. Regardless, survival against heme requires that
cell metabolism is competent, not compromised in any way,
and thus able to provide cofactors including oxygen, NADPH
for HOs and obligatory reductases, and also for H-ferritin.
Resistance of porcine endothelial cells to heme toxicity and
heme sensitization required chronic, rather than acute, exposure
due to the induction of HO1, Ferritin, and particularly H-
ferritin (Balla et al., 1992, 1993). Significantly, heme and its
iron, respectively, are required for coordinate induction of HO1
and H-ferritin. When HO1 is induced by chemical oxidative
stress, cyto-protective ferritin is not induced, at least in murine
macrophages (Sheftel et al., 2007). Notably, cellular metabolism
is disturbed in severe illness, particularly sepsis (Langley et al.,
2013, 2014; Tsalik et al., 2014), which limits the role of HO and
ferritin among other protective mechanisms inmitigating oxidative
damage.
The Clinical Relevance of Hemoglobin,
Hemopexin, and Haptoglobin Levels
In humans, both HPX and Hp are developmentally regulated and
hepatic synthesis is considered the predominant source of plasma
protein. HPX is also produced in several immune-privileged sites
including human brain neurons (Morris et al., 1993), neural
retina photoreceptor cells, and ganglions (Chen et al., 1998);
whereas Hp is in adipocytes, macrophages, and neutrophils1
and is induced by TNF-α in differentiated human adipocytes
(Wang et al., 2005). As previously reviewed (Smith, 2011b),
1FDA Workshop on artificial hemoglobin. http://www.fda.gov/downloads/
BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/Transcript
sMinutes/UCM051545.pdf.
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human HPX and Hp gene regulation have not been extensively
studied. Both promoters contain sites and additional regulatory
regions for the inflammatory cytokine, IL-6 (Poli et al., 1989)
(but unlike Hp, HPX is not an acute phase reactant in humans).
The HPX promoter drives brain and liver expression (Tolosano
et al., 1996). Monkey and mouse HPX genes are regulated by
heme (see Section Improving Animal Models of Human Disease
in which Hemopexin and Haptoglobin Play a Protective Role
Below). Human hepatoma HepG2 cells secrete Hp but not HPX.
Human Hep3B cells may represent fetal, rather than adult, liver
(Oliviero et al., 1987). Hp is induced by IL-6 in this line (Oliviero
and Cortese, 1989) and also by IL-1 but is independent of IL-6 in
HepG2 cells (Baumann et al., 1990).
HPX is very low in newborns and increases (inmg/100ml)
from average of 60 (range 40–70) at 1–12 years to average of 77
(range 66–100) at 20–40 years but then declines at 50–70 years
(range 50–80, Hanstein and Muller-Eberhard, 1968).
The extent of IVH is clinically evaluated from the extent
of plasma Hp depletion and increased Hb; plasma heme and
HPX are not included. Recent longitudinal studies in patients
provide insight into diverse conditions where a high hemolytic
index rate, based principally on plasma Hb, was due to the
inability of Hp/CD163 to function normally and clear Hp-Hb.
Thus, in the presence of a high human immunodeficiency
virus (HIV) load (Delanghe et al., 2010) HPX was depleted
in a patient who presented with symptoms of severe sepsis
or hemo-phagocytic syndrome. Blood, plasma, and urine were
monitored periodically over 70 days to assess liver, kidney, and
muscle function (Delanghe et al., 2010). Free Hb levels were
1.68 g/l (normal <0.11 g/L); Hp levels were 3.37 g/L (reference
values 0.3–2.0 g/L), and HPX was essentially undetectable
(reference values 0.4–1.5 g/L). After admission, indicators of
heme catabolism (i.e., total and direct bilirubin levels) were
normal, but blood monocytes expressed slightly lower than
normal CD163 levels. Plasma lactate dehydrogenase (LDH),
an indicator of tissue damage, was elevated ∼10-fold above
normal. C-reactive protein was increased and serum creatinine
was initially above normal. In the urine, Hb but not heme was
detectable. High levels of Hb-Hp complexes were detected in
the plasma by starch gel electrophoresis followed by staining
for heme (from its peroxidase activity). The circulating Hb-Hp
levels declined as the viral load decreased in response to anti-
viral therapy, as did C-reactive protein and creatinine, indicating
less oxidative stress. The HIV particles likely competed for
CD163, limiting Hp-Hb clearance. This patient presented with
the Hp2-2 phenotype, shown to confer the worst prognosis of
recovery from uncontrolledHIV (Delanghe et al., 1998; Delanghe
and Langlois, 2002). The initial abnormally high Hp levels
were considered to be due to hepatic induction in response to
inflammatory mediators and since infection and inflammation
affect monocyte/macrophage function. After an initial decline
over the first 6 days they increased to within the normal range
at day 16 and nearly doubled by day 70. HPX levels were very low
initially (0.1mg/ml), undetectable at day 6 but increased at day 16
to within the normal range (0.8mg/ml) and slightly more by day
70 (1.0mg/ml, Figure 1). Liver and kidney function improved
as the viral load declined. These and other data (see Section
The Clearance of Hemoglobin by Hemopexin and Haptoglobin
during Extravascular Hemolysis, below), demonstrate that key
responses in the metabolism and regulation of HPX and Hp are
needed to manage a heme load fromHb. In this patient, HPX and
Hp responded individually between day 6 and 16, thus providing
an interesting time frame for future studies on plasma protein
therapeutics.
Significantly, heme and iron and their binding proteins
HPX and transferrin link nutritional immunity with the innate
immune system. Also, CD163 links hemolysis and Hb clearance
with the immune response because it acts as a pattern
recognition receptor, which binds bacterial surface proteins
(Fabriek et al., 2009), and an innate immune sensor for bacterial
or local inflammation. Crosslinking of CD163 with antibodies or
interaction with bacteria mediates release of pro-inflammatory
cytokines (van den Heuvel et al., 1999; Polfliet et al., 2006;
Fabriek et al., 2009). Whereas, binding of Hb-Hp1 to CD163
directs the secretion of anti-inflammatory IL10 (Philippidis et al.,
2004), although Hb-Hp-2 does not. CD163 induces a cascade
of intracellular signals (Ritter et al., 2001) that involves tyrosine
kinase-dependent calcium mobilization, inositol triphosphate
production, and secretion of inflammatory IL6 and colony
stimulating factor 1. Thus, CD163 functions, in an Hp-type
dependent manner, to both activate and suppress the innate
immune response.
Hb clearance from the plasma by Hp will depend
principally upon the number of viable, functioning CD163+
monocytes/macrophages in the body. Hb removal was impaired
in cells exposed to a drug conjugate of a monoclonal antibody
drug compound, gemtuzumab oozogamicin, a biological drug
used to treat acute myelogenous leukemia, which also lowers
the number of CD163+ cells (Maniecki et al., 2008). Perhaps
consequently, this compound also increased vaso-occlusive
disease in the absence of bone marrow transplantation (Giles
et al., 2001). Gemtuzumab has now been withdrawn.
A high hemolysis index in the absence of hemolytic events
occurred in response to the metabolism and heme clearance of
the second generation Hb-based oxygen carrier blood substitute,
pyridoxalated Hb polyoxethylene conjugate (PHP; Drieghe et al.,
2013). Hb-based blood substitutes, under development for 40
years2, are required for highway accident victims, battlefield
casualties, transfusions when an immunological match is not
possible or to replace transfused blood refused for religious
reasons. Biochemically, they are needed to increase oxygen levels
to tissues in the shift from hypoxia to more normoxic conditions
in the capillary beds for endothelial cells and the underlying
smooth muscle cells to restore their normal metabolism. This
process is affected by blood flow rates as well as Hb levels and O2
unloading from Hb. Patients respond to decreased O2 carrying
capacity of blood by increasing cardiac output and ventilation
with pulmonary vasodilation, and at the cellular level there is
a shift to anaerobic glycolysis. ATP released from RBCs binds
to ATP receptors on endothelial cells and induces nitric oxide
2Workshop on artificial hemoglobin. http://www.fda.gov/downloads/
BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/Transcript
sMinutes/UCM051545.pdf.
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FIGURE 1 | Model for the development of HPX depletion states. This
model is based on data from rhesus monkeys given heme i.v. (Foidart
et al., 1982), HPX metabolism studies in humans (Foidart et al., 1983),
known induction of HPX by heme (Smith, 1999; He et al., 2010), normal
recycling of HPX after heme delivery (Smith and Morgan, 1978, 1979), and
HPX catabolism after i.v. administration of heme several fold higher than
the binding capacity of HPX (Sears, 1970; Lane et al., 1972). As
heme-HPX forms in plasma, uptake of this complex by receptor-mediated
endocytosis into liver parenchymal cells raises heme levels. In HPX
deficiency states, heme will traffic unregulated into cells. HOs initially
degrade this heme releasing redox active ferrous iron, CO, and biliverdin,
which is converted to bilirubin by cytosolic biliverdin reductase. Heme also
travels to the nucleus to de-repress Bach 1 target genes including HO-1
and also to induce other genes including the HPX gene. As intracellular
levels of heme rise in liver cells in response to increases in plasma heme,
changes in HPX synthesis and catabolism are reflected in plasma HPX
levels as indicated. Heme is a normal component of bile and as hemolysis
progresses, unregulated heme diffusion into cells raises heme levels such
that any unmetabolized heme can potentially be exported into the bile
(Petryka et al., 1977; McCormack et al., 1982).
synthase. NO binding by Hb could cause vasoconstriction with
a reduction in blood flow.
In an attempt to minimize the toxic effects of blood
substitutes, Hb molecules have been designed to: survive for a
long time in the circulation; bind O2; have a slow rate of heme
autoxidation and scavenge NO minimally. Nevertheless, many
blood substitutes are modified Hb molecules with low or no
affinity for Hp compared with Hb. Hb or heme released from
them into the circulation or interstitial space is potentially toxic.
PHP was designed to treat shock associated with the systemic
inflammatory response syndrome (SIRS), which is an NO-
induced shock with severe hypotension and vasoplegia disrupting
major organ function leading to death. PHP has many anti-
oxidant properties due to a covalent linkage to catalase and
can scavenge NO, and it does not readily oxidize either to
metHb derivatives that do not bind O2 or to ferryl Hb. It was
anticipated to provide treatment in ischemia- reperfusion injury
and hemorrhagic shock, where ROS such as superoxide and
H2O2 and NO are known to be involved. Three patients treated
with PHP (0.25ml/kg/h for max of 150 h 3.5 days 7 and 8 days
peaks hemolysis index 350U, 650, and 900, respectively) were
followed daily for 2 weeks. Plasma Hp levels remained normal
but HPX was essentially undetectable by immune-nephelometry.
Free Hb (measured as PHP Hb with a higher molecular mass
than Hb upon starch gel electrophoresis) was detected in the
patients undergoing PHP infusions. The patient’s Hp could bind
Hb because Hb-Hp complexes formed after Hb addition to
plasma samples collected several days after the infusion occurred.
Throughout this period, total bilirubin, and heme-binding serum
α1-microglobulin levels were normal. Ongoing heme catabolism
was apparent with total bilirubin levels increased for several days
after PHP infusion. One patient had very low HPX levels initially
that eventually rose to low normal levels as their elevated serum
creatinine decreased slightly over the second week; and hepatic
function improved too as the initially abnormally high aspartate
transaminase and alanine amino transferases tended to decline in
the second week. However, lactate dehydrogenase (LDH) levels
were extremely high initially, increasing over days 3–10 then
declining by days 12 and 14. In another patient whose HPX
hardly responded, the LDH levels remained abnormally high.
This group of patients provide an example of heme clearance by
HPX with an increased hemolysis index value but with normal Hp.
HPX will be important in clearing myoglobin (Mb)-heme
from injured muscle in crush injuries. Mb is expressed
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in cardiac myocyte and smooth muscle cells. Mb levels,
normally 30–90 ng/ml, increase 5- to 10-fold (∼500 ng/ml)
after myocardial infarcts (Almog et al., 1987; Sallach et al.,
2004) and in neuromuscular disease (Foidart et al., 1983).
In chronic neuromuscular conditions, heme from Mb affects
hepatic HPX metabolism, as does heme and Hb, in a dose-
dependent manner (see Section Heme Toxicity and Hemopexin
Deficiency States and Refs. Foidart et al., 1982, 1983). In
fulminant rhabdomyolosis, HPX is depleted and Mb levels are
high, while Hp and Hb are normal implicating HPX in the
clearance of circulating Mb (Adornato et al., 1978). Human Hp
binds Hb in preference to Mb (Sakata et al., 1986). In Duchenne’s
muscular dystrophy and polymyositis where there is abnormal
Mb metabolism HPX levels were high.
These patient studies justify adding heme and HPX levels to the
hemolytic index (see Figure 1); and low HPX levels with elevated
LDH may help to distinguish impaired heme plasma clearance
from ongoing hemolysis (Drieghe et al., 2013).
The Clearance of Hemoglobin by
Hemopexin and Haptoglobin during
Extravascular Hemolysis
Mature RBCs will travel ∼300 miles through the systemic
vasculature during their 120 day lifespan enduring deformation
at every twist, bifurcation, and turn, as well as exposure
to changes in osmotic pressure when passing through the
kidney and lung vasculature. This journey is equivalent in
length to 11.5 marathon runs, and the RBCs may traverse
the heart and its valves ∼1,70,000 times. Extra-vascular
hemolysis (EVH) is the phagocytosis of senescent, damaged
or otherwise abnormal RBCs by macrophages in the spleen,
liver, bone marrow, and reticulo-endothelial system. Random
hemolysis—or the age-independent destruction of RBCs -
occurs at a basal rate of 0.05–0.5% daily. Higher rates of
random hemolysis can result in shorter RBC lifespan as does
senescence. The chance of a RBC surviving 100 days is only
61% but only 1% survive 100 days when random hemolysis
increases to 5%3. A compensatory increase in erythropoietin
prevents anemia by increasing RBC production and Hb
levels.
Most pathological hemolysis is EVH with the spleen playing
a major role. EVH is stimulated after one or more blood
transfusions in order to clear any RBCs that have deteriorated
upon storage. In this case, EVH and IVH likely occur
simultaneously, and, depending upon the quality of the stored
blood and the number of transfusions, the hemolysis can expose
cells and tissues to a significant amount of Hb, heme, and iron.
Transfusions can be extensive, for example, car accident victims
may require 100 pints of blood, and there is the potential for a
daily transfusion need during chemotherapy and a lifetime need
in SCD4.
3http://www.uptodate.com/contents/approach-to-the-diagnosis-of-hemolytic-
anemia-in-the-adult
4http://www.redcrossblood.org/learn-about-blood/blood-facts-and-statistics#
blood-components$
After engulfment of RBCs by macrophages, the heme from
Hb leaves the endosomes and reaches the smooth endoplasmic
reticulum (ER) for catabolism by the HOs 1 and 2 (HO1 and
HO2) where each heme molecule stoichiometrically releases
redox active ferrous iron and carbon monoxide (CO). Heme also
moves to the nucleus for gene regulation in part via depression of
Bach1-regulated genes, including HO1 and NADP(H):quinone
oxido-reductase 1 (NQO1). These molecules protect cells against
oxidative stress as levels of redox active heme and iron rise
intra-cellularly. The iron from heme catabolism is either used
for biochemical purposes including translational regulation, or
is stored or exported via ferroportin (FPN1) and delivered
to transferrin. Iron is delivered to liver parenchymal cells by
transferrin or by macrophage-derived L-ferritin (Moss et al.,
1992) from which it may be re-utilized for erythropoiesis
depending upon the body’s needs. The extent of iron export will
be affected by any changes in surface FPN1 levels, including
stabilization by the presence of multi-copper oxidases including
ceruloplasmin (McCarthy and Kosman, 2014), loss due to
proteasome degradation in response to circulating hepcidin
(Nemeth et al., 2004) or increase as heme stimulates FPN1
transcription (Marro et al., 2010).
There is an important role for HPX in EVH after
erythrophagocytosis to accept heme exported by FLVCR, a
member of the major facilitator family of transporters thus
preventing heme accumulation and toxicity (Smith, 2011a,b).
Substrate solutes such as heme will diffuse down a concentration
gradient in this type of transporter but heme export requires
a plasma protein heme acceptor such as HPX or HSA (Yang
et al., 2010). HPX then delivers heme to the liver (Smith and
Morgan, 1978, 1979). Erythrophagocytosis induces HO1 and it is
established that heme degradation by HOs is protective against
heme toxicity in essentially all cell types with ferritin synthesis
and effective heme and iron export. Phagocytic activity is “safe”
for macrophages when they engulf <1.5 RBCs. Subsequently,
40% of the Hb-iron is released in vitro within 24 h. Ingestion
of too many RBCs is lethal in part due to iron toxicity (Kondo
et al., 1988). However, in vitro experiments with macrophage are
not carried out in the presence of in vivo levels of HPX, HSA or
transferrin.
Evidence supports that heme toxicity in macrophages after
erythro-phagocytosis develops either when plasma HPX levels
are low, presumably with concomitant IVH, or if HO1 activity
is compromised. Both scenarios would contribute to raising
intracellular heme levels in macrophages (and also in heme-
exposed endothelial cells). The catalytic capacity of HOs may
become overwhelmed by the amount of intracellular heme
or when there are insufficient substrates and coenzymes for
catalytic activity (O2 and NADPH for the obligatory HO
reductase, cytochrome P-450 reductase). Lowering elevated
intracellular heme via FLVCR-mediated export to HPX is another
solution. However, this route would be compromised when
circulating HPX is low or absent; and exacerbated when the
hydrophobic drug binding site in HSA (Ghuman et al., 2005)
that accommodates heme is occupied by medications. In these
circumstances, α1-microglobulin may provide additional sites for
heme.
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In humans, a relationship between HO1 activity and
HPX metabolism was first apparent in HO1-deficiency with
undetectable HPX levels in a child that succumbed by 6 years
(Yachie et al., 1999), as previously reviewed (Smith, 2011b,
2013); and which is recapitulated in part, in HO1−/− mice
that also have low HPX (Kovtunovych et al., 2010). In both
situations, the key role for macrophage HO1 activity for heme
catabolism and subsequent safe iron distribution in the body
with minimal inflammation is apparent. Also, extensive LDL
oxidation was detected in this patient perhaps from oxidation
of cell free Hb (Jeney et al., 2002) and exacerbated by the HPX
deficiency. Both HO1-deficient mice and humans are anemic
and in the limited number of humans with HO1 deficiency
hyposplenia was found (Yachie et al., 1999), although mice
develop splenomegaly from progressive changes in the spleen
as macrophages become depleted and heme toxicity develops.
As murine HO1−/− macrophages undergo erythrophagocytosis,
they burst releasing their contents, including presumably heme,
into the spleen causing fibrosis in the areas of red pulp. IVH
occurs as senescent RBCs release Hb and heme. The few
remaining CD163+ macrophages in the spleen cannot effectively
clear the Hp-Hb complexes as they do normally. The hepatic
parenchymal cells and kidney proximal tubules are thought
to become new iron storage sites instead of liver and spleen
macrophages. A HPX deficiency state develops in 60% of 8
months old HO1−/− mice, while both Hp and HPX mRNA are
increased in the liver. HPX mRNA increases in the liver lysates
of HO1−/− mice even by 7 weeks of age and HPX mRNA was
also detected at extra-hepatic sites, e.g., in the spleen and kidney,
likely due to induction by heme (Smith, 1999) or perhaps the
inflammatory cytokine, IL-6 (Tolosano et al., 1996). Although,
low plasma HPX and high hepatic HPX mRNA may appear
discordant (Vinchi et al., 2008; Kovtunovych et al., 2010), the
HO1−/− mice likely have high hepatic heme levels; in which case
there is no anomaly because high levels of hepatic heme increase
HPX catabolism without compensatory HPX synthesis by the
liver as shown in humans with hemolytic anemia and in rhesus
monkeys (see Section Heme Toxicity and Hemopexin Deficiency
States). Bone marrow transplantation successfully replenished
normal progenitors ofmacrophages restoring Kupffer cell activity
to the HO1−/− mouse liver (Kovtunovych et al., 2014) and
demonstrating a potential therapeutic strategy.
Successive blood transfusions expose endothelial cells to large
amounts of Hb and heme with IVH occurring simultaneously
with EVH, especially in the initial stages of each transfusion.
CD163-mediated endocytosis of Hp-Hb inmacrophages requires
ATP. How erythro-phagocytosis affects the overall metabolism
of macrophages and how long the cells need to recover the
membrane components including CD163 at their cell surface is
not known in detail. Presumably, significant amounts of energy
are utilized and components of the surface membranes such as
lipids and proteins including CD163 may be catabolized or re-
distributed in the cell. Thus, erythrophagocytosis may decrease
CD163 surface expression with deleterious consequences for
the endocytosis and uptake of Hp-Hb or possibly other
CD163 ligands including Hb in various hemolytic conditions.
Under these circumstances, high levels of metHb are expected
and protection against heme toxicity by HPX will become
significant until there is sufficient replenishment of CD163+
mature macrophages. That this is the case in the clinic is
suggested by data obtained during cardiopulmonary bypass
(CPB) that entails extracorporeal blood circulation, including
priming of the circuit with stored blood and potentially also
blood transfusions. Patients with compromised liver function,
especially liver cirrhosis and a history of alcohol abuse will not
readily synthesize HPX (Vladutiu and Kim, 1981), transferrin
and Hp—all extracellular anti-oxidants against heme and
iron.
Pediatric patients are especially at risk during CPB due to
their lower endogenous HPX levels and need to avoid iron
loading, which can lead to problems in neurodevelopment later
in life, including decreased IQ, motor deficiencies, impaired
language skills, and a higher incidence of behavioral and attention
problems (Lull et al., 2008). In neonates especially, surgery-
related pathology can occur even with great precautions and
improved technology. HPX levels were analyzed by immuno-
blot in plasma samples taken just before CPB, 5min into CPB,
at the end of CPB and then 1 and 24 h post-CPB. In 5/13 proteins
that changed, HPX and the serine protease inter-α-inhibitor 4
decreased; furthermore copper and Hb levels increased while
iron decreased. Although on a non-linear timescale, HPX levels
dropped 60% at initiation of CPB and remained low until the end
of CPB, then increased to about 75% of the initial value. Hb levels
increased from 20 to 60mg/dL during CPB, and had returned to
normal by 24 h post CPB. No changes in Hp were reported in
this study. This rapid, dramatic decrease in HPX levels suggests
that the primed blood had generated significant levels of heme to
deplete circulating HPX levels and that the heme-HPX complex left
the circulation via the liver.
Studies on Patients with Hemolytic
Diseases Reveal Complex Relationships
between Hemopexin and Haptoglobin
Levels
Heme sequestration by HPX, its extracellular anti-oxidant
function, directly protects cells against heme toxicity;
furthermore, heme transported to the liver affects HPX
metabolism (see Section Improving Animal Models of Human
Disease in which Hemopexin and Haptoglobin Play a Protective
Role). Thus, pinpointing when plasma heme levels rise and the
response of HPX will aid in the diagnosis, development of targeted
plasma therapeutics, and patient treatment. Plasma HPX levels
were first proposed in 1975 to reveal the severity of hemolysis
(Muller-Eberhard and Liem, 1975) when grafted heart valves
malfunction. HPX infusion therapy for patients with myocardial
infarcts was first proposed in 1993 (Muller-Eberhard and Fraig,
1993). It was noted that this would be simpler technically than
measuring CO exhalation, the number of deformed RBCs
(schistocytes), serum LDH and urine hemosiderin excretion or
the half-life of radioactive RBCs as indications of the extent of
hemolysis. Also, plasma Hb levels are compromised by hemolysis
during blood collection and storage unless special care is taken.
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The clinical units for plasma proteins are inmg/100ml;
whereas, molar units and stoichiometry reveal ligand clearance
by transport proteins. One molecule of HPX binds one molecule
of heme (Drabkin, 1971); based on an average adult HPX plasma
level of 770µg/ml,∼6.3µg heme would be bound per ml plasma
and higher heme levels would deplete HPX unless recycling
takes place or rapid compensatory synthesis takes place (Muller-
Eberhard et al., 1968). Inmolar terms and based on heme binding
by HPX in mammalian sera, the HPX levels are ∼12.44µM
(Drabkin, 1971) = 1.8 × 1019 molecules in 2.23 L av. plasma
volume based on 55% of 4.7 L blood volume5. Normal plasma
heme rarely exceed 5mg/100ml plasma (∼78µM) using a
modification of the benzidine method. At >10mg heme/100ml,
methemalbumin accounted for ∼65% of the plasma heme and
HPX was often decreased in such plasma. Patient samples often
had>20mg heme/100ml and 325mg/100ml has been measured
in malaria (Sears, 1968). It is generally accepted that plasma Hp
is depleted when plasma Hb is >50–200mg/100ml. Hb then
passes through the kidney glomeruli and some is retained by
the proximal tubular cells where the heme-iron is converted to
hemosiderin (detected as urinary iron). Tubular cells are later
shed into the urine producing hemosiderinuria and unabsorbed
Hb is excreted in the urine (hemoglobinuria). Notably, plasma
schistocyte count and urinary hemosiderin, a measure of excess
RBC destruction, correlate inversely with HPX levels (Eyster et al.,
1972).
In the early 1960’s and early 1970’s, the groundwork for our
understanding of the changes in plasma HPX levels in response
to increased plasma heme during the course of hemolytic events
and human inherited hemolytic diseases was laid by Muller-
Eberhard’s group with additional longitudinal patient studies
by Sears. Although the patient number is relatively small in
these studies, key facts about HPX function and metabolism are
apparent. Both groups provided evidence for a complex, non-
linear but significant, relationship between plasma HPX and
heme levels (but not Hb); whereas Hp levels were related to Hb
levels not heme (Muller-Eberhard et al., 1968; Sears, 1968); see
also Section Heme Toxicity and Hemopexin Deficiency States).
HPX catabolism did not require Hp depletion; thus, Hp and
HPX often simultaneously protect against the development of
heme toxicity from Hb. As previously reviewed (Smith, 2011b),
comparison of the extent of exogenous heme clearance with HPX
levels supported that HPX recycles after heme delivery to the
liver (Muller-Eberhard et al., 1968; Drabkin, 1971), which was
subsequently shown directly using radioactive heme-125I-HPX in
rats (Smith and Morgan, 1978, 1979) and confirmed in human
hepatoma cells (Smith and Hunt, 1990). These findings remain
particularly relevant for and important in the development of
plasma protein therapeutics with HPX and/or Hp.
In many inherited hemolytic diseases, episodes of heme
toxicity occur in a background of chronic oxidative stress and
inflammation, as in mice models of SCD (see Section Key Roles
for Heme Toxicity in the Pathogenesis of Sickle Cell Disease and
Protection by HPX). Sepsis can also entail prominent episodes
of hemolysis that are ameliorated by HPX supplementation (see
5http://anthro.palomar.edu/blood/blood_components.htm
Section Key Roles for Heme Toxicity in the Pathogenesis of Sepsis
and Protection by Hemopexin). Assessment of the association
of HPX levels with the presence of specific diseases, response
to therapies, and prognostication of clinical outcomes requires
longitudinal studies. These involve repeated monitoring of risk
factors and/or outcomes, often on a daily basis. Ideally, the
controls will possess similar baseline characteristics as cases, with
the primary differences being only the exposure of interest. Both
HPX and Hp levels can change quickly in response to a hemolytic
episode that “resolves” generally within 1–2 weeks. To a certain
degree, the early research on HPX and Hp provides a unique
window on the unfolding events affecting the metabolism of
these proteins during and after hemolysis—and in the presence
and absence of infection. The circulating plasma levels of Hp,
HPX, and HSA vary quite widely within the normal population,
but are stable for a healthy individual. Cohort studies that use
data from much larger groups of patients, which share common
characteristics and exposures, are the backbone of current
proteomics and outcomes research. Large group cohort studies
can be carried out prospectively or retrospectively with differing
exposures to a suspected factor or treatment; and then observed
and tested generally. Given the relatively rapid changes in HPX
and Hp levels, frequent sampling may be necessary to identify
correlations between changes in HPX and Hp metabolism and a
patient’s clinical status.
Decreased plasma HPX levels in hereditary hemolytic diseases
was first reported in a study of 38 children in 1963 (Muller-
Eberhard and Cleve, 1963). Haptoglobinemia, defined by a lack
of detectable Hb binding in plasma, was found in spherocytic
anemia with HPX deficiency in 50% of the children before
splenectomy to reduce hemolysis; after which Hp was restored in
50% of the children and HPX in all of them. Hp was undetectable
in 50% thalassemia major subjects but increased in 100% after
splenectomy, whereas HPX only increased in one patient. HPX
levels in thalassemia minor were apparently normal, which may
reflect the lower levels of heme circulating in that condition.
In children with SCD, Hp was low in all cases and HPX was
found to be decreased in all but one subject. A later report
showed that both HPX and Hp are depleted in sickle cell anemia,
sickle cell-HbC disease or thalassemia major (Muller-Eberhard
et al., 1968). HPX and Hp were depleted simultaneously in two
patients with severe hemolytic reactions to blood transfusions,
one linked to anti-E antibodies. There are even cases where HPX
levels are normal although Hp has disappeared from the plasma
(see also Section Structure and Function of Hemopexin and
Haptoglobin and their Role in Heme and Hemoglobin Clearance
in Intravascular Hemolysis).
Some early longitudinal studies revealed that HPX levels were
restored to normal far more quickly than Hp levels after a
hemolytic episode from a variety of causes (Sears, 1968). After
each acute episode, heme levels generally spiked (∼325mg
heme/100ml for example in malaria) within 24 h decreasing to
normal after 6 days and HPX levels start to increase within
24–48 h. However, Hp remained low requiring 14 days to return
to normal plasma levels. This was attributed to a slow ongoing
destruction of RBCs and/or the absence of one or more sufficient
stimuli for de novo Hp synthesis. As described in Section The
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Clinical Relevance of Hemoglobin, Hemopexin, andHaptoglobin
Levels, macrophage clearance of RBCs is vital for heme and iron
homeostasis as it minimizes oxidative stress and inflammation
from heme toxicity (Kovtunovych et al., 2010). We propose
that severe acute or chronic HO1 impairment links decreased
macrophage function in presence of EVH and/or IVH eventually
depleting HPX. However, in relapse from falciparum malaria and
in renal insufficiency associated with an immediate hemolytic
reaction to a blood transfusion (Sears, 1968), HPX and Hp
were depleted and both rapidly restored to normal essentially
immediately after plasma heme levels declined.
Without obvious changes in HPX levels, Hp became depleted
following hemolysis in response to primaquine in erythrocytic
glucose 6-phosphate dehydrogenase deficiency and in relapsed
pernicious anemia (Sears, 1968). In the latter case, 10 days after
vitamin B12 therapy, Hp levels began to increase. Intriguingly,
when the patient developed an infection (pharyngitis, fever and
strep throat) there was a rapid and marked two-fold increase in
Hp levels within 2–4 days without significant changes in HPX
plasma levels, demonstrating that it is not an acute phase protein
in humans (Kushner et al., 1972). Such changes would likely not
be apparent in patient proteomic studies where large numbers of
control and disease groups are compared.
A HPX deficiency with normal Hp levels (76mg/100ml) was
seen in hemorrhagic pancreatitis, where plasma heme was high
at 47mg/100ml (Sears, 1968). Acute hemorrhagic pancreatitis is
an acute inflammation of the pancreas frequently accompanied
by hemorrhages into the gland itself and into the parenchyma
and surrounding tissue. This condition is often fatal due to
the development of shock and multi-organ dysfunction/failure,
particularly the lungs and liver, as well as the development
of disseminated IVH coagulation. The causes generally include
bile duct obstruction (in 50% of all cases), and toxicity from
glucocorticoids, acetaminophen, and thiazide diuretics (Frey,
1979).
Normal or only slightly decreased HPX levels with low Hp
were detected in paroxysmal nocturnal hemoglobinuria and in
auto-immune hemolytic anemia (AHA, Muller-Eberhard et al.,
1968). In AHA patients, Hp was below the normal levels
of 140µg/ml, reticulocyte counts were high (23–70%; normal
levels are 0.5–1.5%) and antibodies to RBCs were present as
shown by positive direct and indirect Coombs test reaction.
The reticulocyte count indicates how fast RBC precursors,
reticulocytes, are made in the bone marrow and released into
the blood stream. This is a normal response to blood loss or
premature destruction of RBCs as in hemolytic anemias, which
would also be reflected by low blood Hb levels. Kidney disease
with increased erythropoietin levels will also increase reticulocyte
count.
Normal HPX levels with low Hp was also detected in an
adult patient with hereditary spherocytosis, which is the most
common form of inherited anemia in individuals of Northern
European descent. Mild or severe anemia is due to genetic
defects in proteins including ankyrin (ANK1 gene) needed for
normal flexibility of red blood cell membrane. These misshapen
cells are recognized and taken up by the spleen and destroyed,
often necessitating multiple blood transfusions. HPX levels were
found to be normal (400µg/ml) and Hp was low but rose ∼5-
fold to 600µg/ml after splenectomy (Muller-Eberhard et al.,
1968).
Overall, these and other clinical studies (Section The Clinical
Relevance of Hemoglobin, Hemopexin, and Haptoglobin Levels)
demonstrate a need to examine the often stated concept,
originating from the late 1960’s, that HPX is depleted only
when Hp is absent (Gladwin and Ofori-Acquah, 2014). HPX
levels decline when a substantial amount of heme is present
in plasma because as hepatic heme increases, HPX catabolism
exceeds de novo synthesis in humans and rhesus monkeys (see
Section Improving Animal Models of Human Disease in which
Hemopexin and Haptoglobin Play a Protective Role). Thus, to
further define the stages and cause of hemolysis and particularly
to distinguish impairment of heme clearance from hemolysis,
knowledge of plasma heme and HPX levels would enhance the
ability of clinicians to define the clinical ramifications.
The Hemopexin System Links Heme and
Iron Metabolism
Evidence for this link comes from different experimental
approaches in humans and animals. Heme-iron recycling
was linked to HPX and heme clearance, by following i.v.
59Fe-hematin (0.77–1.23mg heme/kg body wt.) in IVH from
mechanical damage due to aortic and mitral prostheses; IVH
from paroxysmal nocturnal hemoglobinemia due to complement
destruction of RBCs; and HPX depletion (in the author) after
five injections of hematin i.v. (Sears, 1970). Heme bound to
HPX and HSA immediately but transfers within 3min in vivo
to HPX (Muller-Eberhard et al., 1969; Drabkin, 1971). Body
surface counting showed, as expected, most radioactivity in the
liver rising over 1–2 days and in the spleen increasing over
the first 24 h (∼20% dose) before reaching a plateau that was
maintained for 21 days. Counts rose over the sacrum within
this time supporting rapid re-utilization and 59Fe was rapidly
detected in the RBCs. There were no changes in plasmaHPX, Hp,
or bilirubin; and no detected in the urine. In normal subjects, the
heme-iron was incorporated into circulating RBCs within 48 h,
reached 20% dose in about a days, 37% dose in 3 weeks and 50%
dose over 8–12 weeks. This was noted as slightly slower than
for Hb-iron re-utilization (Garby and Noyes, 1959) or Hb-iron
from effete RBCs (Noyes et al., 1960). Iron status affected heme-
iron re-utilization and more than 60% dose after HPX depletion
and∼70% in the subject with mechanical hemolysis at 21 days. A
detailed analysis was confounded in patients with iron overload
due to dilution of the radioisotope by iron stores.
As described previously (Smith, 2011b, 2013), iron status
affects the HPX system: the surface receptors for heme-HPX and
heme uptake are increased in iron deficiency, and decreased in
iron overload (Smith and Ledford, 1988). HPX delivers heme to
cells where it is broken down by HOs and the iron released. The
heme-iron is stored on ferritin (Davies et al., 1979), or used for
metabolic purposes including an iron source for cell growth for
which an iron-enzyme ribonucleotide reductase is needed (Smith
and Ledford, 1988) or for regulation via the IRP/IRE system of
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proteins of iron homeostasis in human retinal pigment (Hunt
et al., 1996) and human neuroblastoma cells (Hahl et al., 2013).
Oligodendrocytes are the predominant iron-containing cells
in the brain, often clustered around a blood vessel, and provide
support for CNS neurons. Their only known function is myelin
production where iron is a required as a co-factor for cholesterol
and lipid biosynthesis, and for oxidative metabolism, which
occurs at a higher rate in oligodendrocytes than other types of
brain cells (Connor and Menzies, 1996). HPX is proposed to act
in the maturation of oligodendrocytes. As HPX−/− mice age,
there are fewer mature OLs and more precursor cells although
brain iron accumulates. The density of myelinated fibers in the
basal ganglia and in the motor and somatosensory cortex of
HPX−/− mice decreased at 2 months (equivalent to a young
human adult), with decreased neuromotor function (Morello
et al., 2011).
Heme Toxicity and Hemopexin Deficiency
States
Coordination of Extracellular and Intracellular
Defenses May Be Needed under Specific
Circumstances to Survive Heme Toxicity
Oxygen radical reactions occur upon tissue damage and heme
with its redox active iron participates in such reactions that can
lead to the degradation of proteins, lipids and carbohydrates
and nucleotides (DNA and, likely, also RNA). Cells rely
on the proteins in extracellular fluids to limit such radical
chemistry by converting pro-oxidant forms of iron to less
reactive forms (Halliwell and Gutteridge, 1990). HPX is one
of these extracellular anti-oxidants as are Hp, transferrin and
ceruloplasmin. Only HPX, not Hp, inhibited hemin-stimulated
lipid peroxidation providing direct evidence for HPX as the
primary extracellular antioxidant protector against heme toxicity
in biological fluids (Gutteridge and Smith, 1988). There are
numerous examples of this: HPX prevents heme uptake into the
aorta (Bui et al., 2004) and endothelial cells while targeting heme
to the liver (Smith and Morgan, 1979).
In addition to IVH and EVH, sources of heme in vivo would
include rupture of atherosclerotic plaques and trivial hemolysis
in areas of turbulent blood flow such as the bifurcations of major
blood vessels may create areas of sensitized endothelial cells.
Heme (1–7µM) sensitized porcine aortic endothelial cells in
vitro to subsequent oxidative stress leading to cell death (Balla
et al., 1991b). Either a bolus of H2O2; gradual levels of H2O2
generated enzymatically by xanthine and xanthine oxidase or
ROS produced by phorbol ester activated neutrophils (human
polymorphonuclear cells) were toxic. When heme was bound by
HPX (i.e., presented as a 1:1 stoichiometric mixture of heme and
HPX) there was no endothelial cell toxicity (Balla et al., 1993), as
expected because endothelial cells lack of HPX receptors (Smith
and Morgan, 1979). Protection against heme toxicity was also
conferred by catalase but not by SOD supporting that H2O2 is the
ROS. If cells were incubated with ROS before HO1 and ferritin
were induced by heme, the endogenous levels were not effective
protection. If ROS exposure occurred a few hours after heme,
both proteins confer protection due to their induction by heme
and iron, respectively. Several other inducers associated with
the inflammatory response and hypoxia are also good inducers
of HO1 but not necessarily ferritin protein levels. Some ideal
of the temporal relationship is provided by studies albeit in a
different cell type. Maximum HO1 protein levels (∼2-fold) are
induced inmouse hepatoma cells within 3–6 h exposure to heme-
HPX, whereas the iron released from heme catabolism may not
induce ferritin via translation until ∼7–11 h (Alam and Smith,
1989; Sung et al., 2000). Endothelial cell death was accompanied
by increased membrane lipid peroxidation. Endothelial cells are
in danger in inflammation with activated neutrophils in close
proximity that marginate along endothelial surfaces in presence of
diverse inflammatory mediators.
Key Roles for Heme Toxicity in the Pathogenesis
of Sickle Cell Disease and Protection by
Hemopexin
There has been evidence, some published over 35 years ago,
that a lack of plasma HPX, or the presence of heme-HPX with
methemalbumin, is an ominous prognosis in sepsis (Larsen et al.,
2010; Jung et al., 2015), as well as hemorrhagic shock (Friedman-
Mor et al., 1978) and liver cirrhosis (Vladutiu and Kim, 1981).
SCD is a really important common disease entity and there is
experimental evidence from in vitro studies with human and
rodent cells as well as SCD mice that heme released from metHb
is a major cause of several pathological symptoms, which are
prevented by HPX in vitro and in vivo. Plasma heme rises
in SCD patients from 0.2 to ∼4µM and may exceed 20µM
(see references in Belcher et al., 2014). Thus, HPX protects by
acting as an extracellular anti-oxidant sequestering the heme and
targeting the heme-HPX complexes to cells that play a role in iron
homeostasis, particularly the liver (Smith and Morgan, 1979).
HPX deficiency develops in SCD, in β-thalassemias and in mice
models of SCD. Several avenues of how this damage is mediated
and how it can be ameliorated have been opened up recently
including the modulation by HPX of the inflammatory immune
response activated by heme.
In SCD, genetic mutations in globin, generate unstable
molecules, HbS, that cause distortions in red blood cell structure,
thus increasing their fragility such that shear forces in blood
vessel forks and capillary bed cause lysis. The ensuing hemolysis
leads to a constant damaging oxidative stress due partly to
the chemical reactions that hemoglobin and heme undergo as
HPX and Hp levels decline. Painful episodes, or “crises,” are
thought to be due to events that precipitate vaso-occlusion in
the presence of chronic hemolytic anemia and also an even
more rapid hemolysis termed “hyperhemolysis.” Heme drives
endothelial cell expression of adhesion molecules to which
platelets and RBCs attach, ultimately blocking blood flow.
Systemic inflammation occurs simultaneously with ROS release,
and, together with ischemia reperfusion injury, whichmay lead to
cerebrovascular compromise (strokes) and organ infarction. The
only cure for SCD is bone marrow transplantation, which carries
significant risks of morbidity and mortality due to immune
suppression or injury induced by the donor immune system
recognizing recipient antigens as foreign (graft vs. host disease).
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Other patient treatments include approaches to avoid vaso-
occlusion crises, palliative therapy to manage pain and to relieve
symptoms, and antibiotic prophylaxis to prevent infections and
pneumonia. New treatments include gene therapy to produce
normal Hb, drugs to produce fetal Hb (which lack the abnormal
beta subunits that cause hemoglobin polymerization and RBC
sickling), NO therapy to prevent sickle cell clumping and statins
to limit cholesterol levels and decrease oxidative stress in blood
vessels6.
HPX deficiency in SCD mice promotes vaso-occlusion
(Belcher et al., 2014) and lung injury, i.e., acute chest syndrome
(Ghosh et al., 2013). The extent of any hemolysis is driven by RBC
instability and the extent of potential heme toxicity by changes
in heme that affect it’s binding to globin. Compared with HbAA
mice, the RBCs in HbSS mice turn over rapidly (t1/2 of 2–5 days)
in a steady state of stasis at ∼8–10%. Infusions of Hb in the
HbSS mice increased stasis to 30%. Co-administration of either
Hp or HPX with Hb prevented stasis, supporting that heme is
the active agent. HbS caused more stasis than HbA consistent
with its known instability and supporting that HbS more readily
releases heme; thus, enhancing the pathology of SCD. Infusions
of HbA into control mice generated low levels of stasis (similar
to saline-induced iv hemolysis). Thus, heme induces stasis in
sickle, not WT, mice. As platelets and RBCs adhere to the walls
of endothelial cells lining blood vessels, the blood flow slows and
vaso-occlusion can occur. Heme must be released from metHbA
to cause the pathology because the stable derivative of heme,
cyanometHb, did not cause vaso-occlusion (36.2% stasis vs. 8.2%,
respectively); nor did mixtures of HbA with methylene blue
(ferro-Hb), or HbA with Hp, or HbA with HPX.
HPX is part of the innate immunity defense and TLRs are
part of the innate immune system to restrict pathogen growth.
Heme activates TLR4 leading to TNFα production in mice
macrophages in vitro (Figueiredo et al., 2007). Using TAK-242
to block the TLR4 interaction with its adaptor molecule, and
with TLR4−/− cells and mice, TLR4 was shown to be needed
for the heme-responsive trafficking of adhesion molecules to the
surface of endothelial cells (Belcher et al., 2014). Importantly,
this pathway and a role for TLR4 has also been validated in
human endothelial cells. HPX prevented the rapid migration of
P-selectin and Von Willibrand Factor (VWF) to the cell surface
in response to heme. HPX also prevented heme stimulation of
Weibel-Palade body degranulation and the increase in surface
P-Selectin and VWR after 24 h incubation with either HbS or
HbA. This response was related to the amount of heme because
the surface expression of P-Selectin and VWF was greater in
response to HbS compared with HbA, reflecting the faster rate
of heme loss from HbS (Hebbel et al., 1988). Inhibitors of
PKC and NADPH-oxidase or inhibition by anti-oxidants such
as N-acetyl cysteine and iron chelators provided presumptive
evidence for the involvement of ROS and oxidative stress as
part of heme-induced WPB degranulation in endothelial cells
and consequent stasis. The NFKB signaling pathway was also
needed in part. Adhesion molecules identified to be involved
6http://www.mayoclinic.org/diseases-conditions/sickle-cell-anemia/basics/
treatment/con-20019348.
in heme-induced stasis in the sickle mice are VCAM1, α4β1
integrin, ICAM-1, PECAM-1, E-selectin, and α4β3 integrin.
Unexpectedly, in mice, inactivation of one of these adhesion
molecules at a time was sufficient to prevent stasis from taking
place. Heme stimulation of surface adhesion molecule expression
in cultured endothelial cells was recapitulated in NY1DD mice
but not controls. P-selectin and VWF expression was detected
on venules of the skin, brain, lungs, liver and kidney. The histo-
chemistry showing EC activation and vaso-occlusion revealed
clear differences in the different tissue capillary beds. Thus,
tissue-specific responses of endothelial cells to: heme, heme
and ROS, heme and inflammatory cytokine stimuli under
either physiological or pathological conditions are expected.
Belcher and colleagues (Belcher et al., 2014), pointed out
that many local factors influence the different vascular beds
e.g., EC heterogeneity, hemolysis, local cytokine milieux, HPX
and Hp levels, HO activity, infections and oxygen gradients
plus local or global changes in hemolytic rates, infection and
hypoxia to trigger vaso-occlusive crisis. To show that heme-
mediated stasis required TLR4 signaling in endothelial cells in
vivo, chimeric NY1DD mice were generated that expressed HbS by
transplanting bone marrow from NY1DD mice into irradiated
TLR4−/− and TLR4+/+ mice. Heme-induced stasis, using heme
in the pathological range of 20–60µM, occurred in the in the
NY1DD/βs/TLR4 +/+ mice or non-transplanted NY1DD mice
but not in the NY1DD/βs/TLR4−/− mice expressing HbS. βs
expression is clearly needed for stasis because the heterozygous
HbAS mice had levels of stasis that were intermediate between
HbAA and HbSS mice.
Although, humans develop more severe lung injury than
mice, heme caused lung injury in SCD mice via neutrophil
extracellular trap (NET) formation, which was limited by HPX
(Chen et al., 2014). NETS are thought to bind and eradicate
pathogens but will also trap platelets and RBCs leading to vaso-
occlusion. Induction of NET formation in the lungs requires
TNFα-activated neutrophils and can precipitate death. These
neutrophils have higher levels of intracellular ROS and also
generate ROS from myeloperoxidase, whose levels increase in
the plasma. Decondensed chromatin is released that has granular
enzymes such as elastase bound to it. The plasma of SCD patients
has more activated neutrophils than non-sickle plasma, and in
crisis contains significantly higher levels of DNA, nucleosome
components, and myeloperoxidase. Heme levels were higher in
the plasma of TNF-α treated SCD mice compared with controls.
Furthermore, heme stimulated TNF-α primed neutrophils to
generate NETs and, as with adhesion factor expression, this was
related to heme concentration. Significantly, HPX reduced NET
release by over 90% when cells were incubated with a mixture of
equimolar amounts of heme andHPX. Heme-HSA, but not HbA,
caused significant NET production, consistent with their relative
affinities for heme. HPX infusion significantly lowered the heme
concentration and reduced the number of pulmonary NETs,
plasma DNA, nucleosome levels, and decreased MPO activity
in SCD mice. Neither heme nor TNF-α alone caused detectable
NETs release. Thus, these heme effects may occur in response to
infection, which would in part explain the development of acute
chest syndrome in SCD patients suffering from acute infections.
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Based on the known specificity and extremely high affinity
of heme binding by HPX, the metHbA-induced stasis in a
background of SCD oxidative stress was due to heme and
HPX protects. Thus, in sterile inflammation with heme-TLR4
activation, heme has been proposed as an erythroid Damage-
AssociatedMolecular Patternmolecule i.e., a DAMP (Gladwin and
Ofori-Acquah, 2014).
Key Roles for Heme Toxicity in the Pathogenesis
of Sepsis and Protection by Hemopexin
Sepsis is defined as SIRS due to identified or presumed infection
and is the leading cause of death in the USA, affecting more than
1 million annually. Of these deaths, 28–50% are estimated to be
due to multiple organ dysfunction syndrome7. Recovery from
sepsis can be difficult and extended, and sepsis survivors may
suffer prolonged or life-long disability. People with weakened
immune systems, infants, and the elderly are most vulnerable
to sepsis, as well as people with chronic illnesses including
diabetes, HIV, cancer, and kidney or liver disease. It is reported
that 70–90% of Ebola virus victims in West Africa in 2014
succumbed to sepsis with multi-organ failure8. This syndrome
is the most expensive condition treated in US hospitals and
cost >$20.1 billion in 20119. Unfortunately, sepsis remains a
clinical diagnosis, due largely to the non-specific signs and
symptoms that patients exhibit during the initial phase of illness.
Earlier diagnosis and effective treatment of sepsis would save
lives. Treatment of sepsis remains limited to supportive care
(particularly vasopressive agents and intravenous fluids), rapid
initiation of antibiotic therapy, and identification and drainage
of sources of infection. Sepsis-specific treatments have been overall
disappointing; however, evidence from mice supports that plasma
protein therapies with HPX and /or Hp could be helpful in reducing
the severity of illness and mortality.
Plasma protein therapies are established as plasma volume
expanders after burns and in septic shock (HSA) and also
infusions of immunoglobulins for certain immune deficiencies.
Japanese and German physicians pioneered Hp infusions to
prevent renal damage from hemoglobinuria in burns and,
in 1977, the severe hemolytic damage accompanying ABO
incompatibility (Homann et al., 1977). In CPB surgery (Tanaka
et al., 1991), Hp was undetectable after 30–90min and
hemoglobinuria developed with renal tubular injury. When
serum free Hb reached >30mg/dL, Hp administration cleared
plasma Hb within 30min, hemoglobinuria and improved kidney
function. Hp infusions together with fluid resuscitation and
plasma administration prevented post burn shock and acute
renal failure in a young man with severe burn injury with lung
damage (Imaizumi et al., 1994). Unfortunately, a second skin
graft 51 days later led to death from sepsis with secondary cardiac
failure. The Hp infusions used were: 2000 U (2840mg) for serum
free Hb 50mg/dL (1000mg/50 kg body wt.) and 4000–8000
7http://www.nigms.nih.gov/Education/Pages/factsheet_sepsis.aspx
8http://world-sepsis-day.org/?MET=SHOWCONTAINER&vCONTAINERID=10
32.
9http://www.infectioncontroltoday.com/news/2014/04/cdc-offers-new-sepsis-
fact-sheet.aspx.
U (5680–11,360mg) for >100mg Hb/dL (4000mg Hp/50 kg,
Yoshioka et al., 1985; Imaizumi et al., 1994).
Two clinical studies provide evidence that low plasma HPX
levels at the time of diagnosis are related to the severity of
sepsis and indicate a poor prognosis for septic shock. The
criteria for sepsis diagnosis used the parameters defined by
the American College of Chest Physicians Society of Critical
Care Medicine consensus criteria (Moreno et al., 1999). In
general, the patients received currently accepted methods of
therapy including aggressive fluid resuscitation, broad-spectrum
antibiotics during the first 24 h, vasoactive agents; together with
one or more doses of hydrocortisone. The mean initial HPX
plasma levels in non-survivors (∼0.6mg/ml) were significantly
lower than those of the survivors (mean ∼1.2mg/ml; Larsen
et al., 2010). In a similar study in Korea, initial serumHPX level in
non-survivors was 0.75mg/ml compared with 1.02mg/mL (P <
0.001) in survivors (Jung et al., 2015). Thus, based on our current
knowledge of how heme toxicity develops, there is every reason to
believe that HPX infusions alone, or together with Hp, would be
therapeutic in the management of sepsis, septic, and hemorrhagic
shock (see Figure 2).
These clinical sepsis data showing that low HPX predicts a
poor prognosis provide a rationale for investigating the role of
HPX infusions as a therapy for HPX deficiency states secondary to
sepsis-induced hemolysis. The first compelling observations that
(i) heme toxicity can be central to the pathogenesis of a human
disease allowing heme toxicity to develop as HPX levels decline
(i.e., a HPX deficiency state); and (ii) HPX infusions restore
circulating HPX levels, reduced mortality, and thus may be a
novel therapeutic approach came from studies usingmice models
of sepsis (Larsen et al., 2010). The foundation was research
with Hmox−/− mice, which revealed that HO-1 induction and
heme catabolism in response to microbial infection suppressed
the development of severe sepsis. Protection was found to be
unrelated to the extent of the pathogen load but was related to
protection against free heme released by hemolysis during the
infection. Thus, non-protein bound heme compromised the host
tolerance to infection.
Protection against heme toxicity by HPX also requires HOs
and their enzyme activity because protection against heme
and heme plus ROS is lost in HO-1−/− neurons and when
HO-1 activity is inhibited by tin-protoporphyrinIX (Li et al.,
2009). Although protection against redox-active iron was not
part of the studies, earlier work (see Section Coordination of
Extracellular and Intracellular Defenses May Be Needed under
Specific Circumstances to Survive Heme Toxicity) and extended
more recently (Vercellotti et al., 2014) showed a key role for
the ferroxidase H-ferritin subunit in spleen and liver to protect
cells in SCD mice; but considered independent of HO-1 activity
(Vercellotti et al., 2014).
Necrosis after toxic heme levels requires several hours so cells
initially appear normal and any responses to heme in the short
term need to be distinguished from possible toxic effects that
only become apparent much later (e.g., after 24 h). HPX also
protects cells from “heme sensitization,” the apoptotic cytotoxic
effect of heme that requires exposure of cells not only to heme
but subsequently to pro-inflammatory molecules such as TNF.
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FIGURE 2 | Kicking heme toxicity. As originally suggested by Delanghe
et al. (2010) and Drieghe et al. (2013), there is at the bedside a currently
unrecognized and potentially quite frequent need to distinguish impaired
heme clearance from ongoing hemolysis. Several major organs may be
involved in the pathology of heme toxicity, including the liver, lungs, heart,
spleen, intestine, and kidney. Certain immune-privileged sites such as the
brain and gonads are initially protected by strong endothelial barriers with
tight junctions, and certain immune-privileged cells exist in an
immunosuppressive environment. Thus, endothelial cells provide a physical
barrier and epithelial cells provide a selective cell gate. Several markers in
blood and urine samples are indicated here, in addition to the standard liver
and kidney function tests and parameters used for the hemolytic index. If
routinely measured, e.g., free heme, free HPX and free Hp in plasma, and
heme in urine should prove useful in diagnosis and help discern when there
is impaired heme clearance due to a HPX deficiency state. As endothelial
cells die and lyse they may be the principal source of plasma HO1 (Ghosh
et al., 2011) and also raise LDH levels (Drieghe et al., 2013). The soluble
ectodomain (sed) of scavenger receptors are released into the circulation by
proteolysis and it is expected that sedCD163 will bind Hb and/or Hp-Hb, and
sedLRP1/CD91 may bind heme-HPX.
Uptake of heme-HPX by primary human or mouse hepatocytes
did not raise ROS levels as did heme, even after subsequent
incubation with TNF for 16 h (Larsen et al., 2010). TNF alone
raised release of HMGB1 from these primary hepatocytes and
this was exacerbated by previous incubation with heme but not
with heme bound to HPX. Thus, HPX prevents direct cytotoxicity
of heme and heme sensitization of cells that is one consequence of
heme exposure.
Low-grade sepsis in response to colon puncture and ligation
is toxic in Hmox1−/− mice but not WT mice (Hmox1+/+) and
i.v. heme promotes tissues damage and leads to a severe “high
grade” sepsis (Larsen et al., 2010). This takes place although
the levels of cytokines produced in the septic inflammatory
response e.g., TNF, IL-6, and IL-10, were similar in Hmox1−/−
and WT mice. Hb levels were above normal in Hmox−/− but
not the Hmox−/+mice. Rodent models of human diseases where
HPX and Hp are protective are complicated by the fact sham
operations, stress, and inflammation alone can lead to significant
increases in both HPX and Hp plasma levels. Nevertheless, the
HPX levels were highest in the WT mice, decreased by about
20% in Hmox1+/− (from ∼2.45 to 2mg/ml) and had further
decreased but were still detectable in the Hmox1−/− mice Mice
start to die as early as 2 days after CLP; however, HPX infusions
(50mg/kg ip) caused a significant decrease in this morbidity from
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75 to 20% when given at 2, 12, 24, and 36 h post CLP. The control
mice were given IgG (50mg/kg ip) and an equal volume of the
solvent control, PBS.
Heme Toxicity in Hemorrhagic Shock and Links
with Hemopexin
Although hemorrhagic shock differs from septic shock
(Wichterman et al., 1980), HPX metabolism is altered in
hemorrhagic fever from Dengue virus, which is transmitted by
infected mosquitoes. HPX levels were 10% of controls in severe
dengue associated with hemorrhagic fever (DHF) and a rapid
drop in platelets, during a dengue epidemic in Thailand (Muller-
Eberhard and Liem, 1975). HPX levels may help determine the
severity of the illness, discriminate between dengue hemorrhagic
fever (DHF) and uncomplicated dengue fever (DF), which
would aid in diagnosis and treatment; and fibronectin, HPX
and transferrin were found to be significantly decreased in DHF
(Kumar et al., 2012). In other studies, HPX and vitronectin were
increased in DF and DHF (Poole-Smith et al., 2014). Although
by no means proven [see references in (Poole-Smith et al., 2014)
on data from other human and swine studies],HPX together with
other biomarkers such as Hp, may prove useful as a supplement
in certain stages of hemorrhagic shock and even, potentially in the
progression of Ebola in patients, especially those that progress to
hemorrhage.
Improving Animal Models of Human
Disease in which Hemopexin and
Haptoglobin Play a Protective Role
Experimental animals allow investigation of tissues not readily
available in humans as well as greater control over response,
sampling, and treatment times; thus, standardization is of prime
importance in good animal models of human disease. The rhesus
monkey (rhesus macaque, Macaca mulatta) is a primate model
with the most similar genetics, physiology, and metabolism to
humans. In contrast, with respect to the response to infection,
mice can tolerate far larger burdens of bacteria than humans
without succumbing and although this differential response
can be bacterial species specific, there are differences between
humans and mice in their response to inflammatory conditions
(Seok et al., 2013). In mice and rats, HPX acts as an acute phase
reactant and there are very rapid and extensive increases in
plasma levels of HPX and Hp (e.g., ∼4–5-fold in inflammation)
induced by a variety of stimuli including sham surgery. These are
far higher than the ∼1.5–2-fold changes documented in humans
in various diseases and conditions. In general, animal plasma
levels of HPX (mg/100ml) are similar to humans (Drabkin,
1971; Lane et al., 1973), e.g., rabbit (31–52), rat (63–82), and
dog (76–128). However, in humans, HPX is not an acute phase
reactant and was not induced by muscle biopsy that caused
an inflammatory response raising Hp among other standard
parameters e.g., fibrinogen and α1-antitrypsin (Elin et al., 1982).
Human HPX is a highly conserved glycoprotein and uniquely
has an N-terminal O-linked oligosaccharide in addition to
five bi-antennary chains (for review, see Smith, 2011b). Heme
coordination is identical in human, rabbit, bovine, and rat
HPX based on a variety of physic-chemical data including
absorbance, electron paramagnetic resonance and magnetic
circular dichroism spectroscopy. However, there are clear
differences between the HPX and Hp systems in humans and in
rats including species differences in receptor affinity.
One way forward to better understand the metabolism and
the roles of HPX and Hp in humans is to compare directly
the structure and function of human and mouse proteins and
their receptor interactions in vivo and in cultured cells in vitro.
Significant differences in the high affinity of human Hp-Hb for
human HuCD163 compared with that of mouse Hp-Hb for
mouse CD163; and between the high affinity of mouse Hb for
mouse CD163 compared with human Hb for human CD163 as
well as in vivo uptake supported that in humans Hb clearance
is principally via receptor-mediated uptake of Hp-Hb but not in
mice (Etzerodt et al., 2013). It would seem that additional studies
in humans are still needed to determine the extent of involvement
and relative contributions of the role of the liver and macrophages
in Hp-Hb clearance and at what times during the course of the
development of disease-related pathology.
The normal plasma clearance in rats of human and rabbit
HPX is faster than that of rat HPX (Liem, 1976). There are
differences in the affinity of human, rabbit and rat HPX for rat
hepatic HPX receptors that affects the rate of heme clearance
from the circulation and the extent of liver heme uptake from
59Fe-heme bound to 125I-labeled human, rabbit or rat HPX in
rats (Smith and Morgan, 1979). More complex was taken up
and more heme delivered to the liver within 5–15min in the
order human > rabbit > rat HPX complexes supporting that
human HPX has a higher affinity for the rat HPX receptors
than rat HPX. All three species of HPX interact with a common
receptor on liver cells because increasing the levels of circulating
complexes, led to similar hepatic saturation levels [∼200 pmol/g
of liver for both rat and rabbit HPX (Smith and Morgan, 1978)];
and competitive inhibition studies showed that non-radiolabeled
rabbit heme-HPX complexes blocked radiolabeled rat heme-
hemopexin uptake. In these experiments, no extensive catabolism
of 125I-rabbit HPX occurred; supporting that the chloramine-
T iodination, carried out under oxidizing conditions, had not
denatured the protein which would then have been rapidly
degraded by the liver. Furthermore, the heme levels used were
low enough to minimally affect HPX metabolism.
Endothelial cells are clearly a heme target in SCD; also HO1
is increased in renal tissues of SCD patients but not in the
Townes and Berkeley mice model of SCD (that are on identical
backgrounds, Ghosh et al., 2011). Circulating endothelial cells,
shed from the vascular wall lining into the bloodstream, are
rarely seen in normal individuals but are in SCD and may reflect
vascular damage/dysfunction. The responses of cytoprotective
enzymes to heme in vitro were found to vary depending
upon the duration of heme exposure and origin of endothelial
cells. Primary human endothelial cells from the pulmonary
artery (PAECs) and microvasculature (PMVECs), and dermal
microvasculature were incubated with multiple exposures to
heme (5–25µM), considered not toxic, in fresh media every
48 h for 7 days. Five genes differentially regulated by heme in
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PMVECS and PAECs were shared: HO1, glutamate-cysteine-
ligase modifier subunit, NQO1, H-ferritin and δ-aminolevulinate
synthase 1. Nrf2 regulation was considered central: whereas HO1
was quickly induced by heme, NQO1 required several days and
was apparent only in the older mice perhaps due to the oxidant
burden of the disease and low levels of endothelial SOD. NQO1
staining was more intense in clinical SCD than in mice. One
similarity between the mice and clinical SCD was the intensity of
HO1 staining in post-mortem lung endothelium, although HO1
mRNA levels were highly variable in the patients. Plasma HO1
levels from SCD patients varied considerably, but correlated with
markers of endothelial cell activation and injury. These enzyme
changes may provide a strategy for additional SCD therapy
(Ghosh et al., 2011).
Patients and rhesus monkeys were used to investigate why
serum levels of HPX are abnormal in hemolytic anemias, chronic
neuromuscular diseases, and acute intermittent porphyria. The
synthetic and fractional catabolic rates of HPX were measured
in patients exhibiting low, normal, or elevated serum HPX
levels (Foidart et al., 1983). Elevated HPX levels principally
reflected increased synthesis not decreased catabolism of HPX:
the mean synthetic rate (13 ± 1.0mg/kg/day) was twice that
of the patients with normal HPX levels (6.6 ± 0.3mg/kg/day),
whereas the fractional catabolic rate was ∼ 33% higher than
controls (i.e., 35.3 ± 7.1% of the i.v. pool per day compared
with 26.5 ± 0.8 for controls). Low serum HPX in patients
with SCD appeared to be due to increased HPX catabolism
(36.0 and 40.0% of the i.v. pool per day vs. 26.5 ± 0.8 for
controls) without compensatory synthesis. Clinical conditions in
which serum HPX levels are either increased (acute intermittent
porphyria, chronic neuromuscular diseases) or decreased (severe
hemolysis or rhabdomyolysis) were simulated in rhesus monkeys
by administering heme i.v. daily over 10 days (Foidart et al.,
1982). Low heme (0.02–0.04mg/kg/day) increased serum HPX
levels by 50% (control = 53.3 ± 2.8 U/100ml) due to a
76% increase in the net rate of HPX synthesis, that enlarged
the IVH pool size of HPX by 65%. An intermediate heme
dose (0.6mg/kg/day) caused a 43% increase in the rate of
HPX synthesis balanced by a 33% increase in catabolism; and
HPX serum levels were unchanged. High heme (5.0mg/kg/day)
decreased HPX to 60% of control due to a 57% increase in
HPX catabolism without a concurrent increase in synthesis. HPX
metabolism reached steady state within 4 days of heme exposure;
and both 125I-human and monkey HPX were metabolized in
the same way. HPX was specifically regulated by heme because
plasma transferrin and Hp were unaltered. These findings support
a relationship between the amount of heme presented to the liver
and net HPX turnover; and implicated, for the first time, a role
for hepatic heme levels in HPX regulation. Consistent with these
observations, heme induces HPX mRNA in murine hepatoma
cells (Smith, 1999) and primary embryonic rat neurons (He et al.,
2010). From other studies but relevant here, raising plasma heme
did not alter the half-life of HSA as it does HPX. Furthermore,
HSAwas cleared faster than rabbit albuminwith half-lives of 125I-
HSA and heme-125I-HSA compared with rabbit albumin and
heme-rabbit albumin [3.25–3.75 days compared with 4.5–5.25
days (Liem et al., 1975)].
This research in monkeys demonstrates the advantage of
investigating the response of HPX to a wide range of heme
concentrations based upon human studies, especially low levels.
Most studies use a single, pharmacologically toxic high heme
dose, e.g., a 50-fold excess of theoretical/possible HPX binding
(Lane et al., 1973). Heme is a normal constituent of bile in
humans 12.6 nmol/h compared with 8.2µmol/h bilirubin. Heme
administration (6.4µmol/kg) increases heme (109.5 nmol/h) not
bilirubin (McCormack et al., 1982). Higher amounts of heme
administered i.p. in rats (5–40mg/kg body weight) causes bile to
turn black [heme at 0.29mg/ml (Petryka et al., 1977)]. However,
whether this is due to unregulated diffusion via the FLVCR
heme exporter or a normal entero-hepatic circulation of heme
is not established. In rats, at low doses of heme (47 nmol/100
g body weight) based upon 10 × the daily heme requirement
of humans relative to body weight, there is extensive heme
catabolism in duodenal enterocytes. Because only iron reached
the circulation bound to transferrin, no heme-HPX was detectable,
these data revealed that duodenal enterocytes are the first point
of convergence of heme and iron metabolism in the body (Smith,
1990, 2009, 2011b).
The genetic background of mice affects their iron status, and
the iron status of mice and their strain affects Hp expression in
different ways depending upon the response of the ER unfolded
protein pathway to iron load (Faye et al., 2007). There was a
significant decrease in liver and serum Hp in C57BL6 mice but
not the 129sv strain, fed an iron-rich diet. The chaperone for
protein folding in the ER, glucose regulated protein, GRP78,
was decreased in the C57BL6, but not in the 129sv, mice. Iron
overload negatively impacted Hp synthesis likely by creating
oxidative stress in the ER. Then incorrectly processed and folded
Hp is degraded upon GRP78 depletion. It is not known if this
affects the metabolism of Hp, whose regulation is stabilized in
the HPX−/− mice (Tolosano et al., 1999), which are on the 129sv
background.
Overall, these animal studies demonstrate and re-inforce the
conservation across species of the protective role of HPX against
heme toxicity, the development of HPX deficiency states, and show
how raising heme and iron levels in the liver makes an impact on
HPX and Hp synthesis and metabolism.
Concluding Remarks
In this article we have outlined the deleterious physiological
consequences of IVH free heme and the role these effects play in
the development and complications of various disease processes
in humans. HPX’s actions, biological roles, metabolism, and
function have also been studied in rhesus monkeys, dogs, rabbits,
rats, and HPX−/− mice (Tolosano et al., 1999, 2002; Morello
et al., 2007; Fagoonee et al., 2008; Vinchi et al., 2008; Li et al.,
2009; Chen et al., 2011).
Relevant to human disease: (1) HPX sequesters heme from
cells preventing direct cytotoxicity and heme sensitization; and
in cells lacking HPX receptors this prevents endothelial and
immune cell activation leading to stasis and exacerbation of
the inflammatory response, respectively; (2) Plasma HPX targets
heme principally to the liver and normally recycles intact after
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receptor-mediated endocytosis while the heme is degraded and
its iron re-claimed; (3) Hepatic uptake of heme-HPX is via a high
affinity low capacity system, likely LRP1/CD91, and a low affinity
high capacity system (Smith and Morgan, 1981; Smith, 2013);
(4) Heme transfers rapidly in plasma from albumin to HPX;
(5) Plasma HPX levels are linked to plasma and hepatic heme,
not plasma Hb levels or the acute phase response; (6) Changes
in plasma HPX levels reflect the balance of hepatic synthesis
and secretion of HPX with HPX catabolism; HPX declines
with increased hepatic heme as HPX catabolism overshadows
compensatory synthesis; (8) HPX metabolism responds to heme
from Hb and Mb; (9) HPX protects erythrophagocytosing
macrophages from heme toxicity in EVH; (10) HPX functions
independently of and simultaneously with Hp and does not
require global Hp depletion. As we strive to improve animal
models, two current challenges to accurately describing Hb
metabolism lie in the differences in Hb-Hp metabolism in
CD163+ human macrophages compared with these cells in mice
and the lack of a reliable, high throughput assay to detect and
quantitate in plasma Hb-Hp, heme-HPX, and methemalbumin.
Incorporating this contemporary understanding of heme
metabolism into the evaluation of disease states prominently
characterized by hemolysis may likely prove valuable in a variety
of ways, including: (1) providing accurate diagnosis of acute
illness; (2) improving our ability to determine which patients
are at greater risk for more severe illness, complications, or
death; and (3) developing targeted replenishment therapies for
patients suffering from acute illnesses due to, or exacerbated
by, significant hemolysis. However, large gaps remain in our
understanding of heme metabolism and the role that HPX and
Hp could play in specific disease states. In addition to the bench-
side experiments using animal models that have provided much
of the knowledge to date on the roles of HPX andHp in heme and
Hb metabolism, respectively, translational approaches that use
human-derived samples from patients with and without specific
diseases and/or risk factors are warranted.
Future studies in human subjects should focus on several
common diseases that often feature, or are complicated by,
hemolysis. These diseases include SCD, sepsis, hemolytic
anemias, and viral hemorrhagic fevers (e.g., Dengue, Ebola, and
Marburg). Sepsis and SCD in particular have readily-available
animal models and baseline data, and disease incidence is
sufficiently common to allow both acute and longitudinal studies
in humans. Future studies should be conducted to determine
HPX levels in these disease states, to assess the discriminatory
ability of HPX for disease in symptomatic and/or at-risk
individuals, and to determine the prognostic utility of obtaining
HPX levels in acutely-ill patients. When assessing severe illness
characterized by prominent hemolysis, physicians currently use
hematological profiles that quantitate cellular components and
measure coagulation function.We propose that including plasma
heme and HPX measurements as adjuncts to these standard
hematological assays may further enhance the diagnostic and
prognostic capabilities of the hematological profile, thereby
enhancing clinical decision-making. An international standard
for plasma heme and HPX, as previously suggested (Delanghe
and Langlois, 2001), is called for and will make defining heme
toxicity risk more accessible and easier to interpret. Finally,
many disease states characterized prominently by hemolysis
lack targeted therapies. Investigating the role of replenishment
therapies, particularly with HPX to sequester heme, may prove
beneficial for these patients and in a plethora of clinical situations
including cardiac surgery, blood transfusions, and patients with
a high risk of developing sepsis (e.g., with burns, trauma injury,
bed sores in the intensive care units or who have alcoholism).
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